Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Summary

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma. The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.

Timeline

Start

2020-12-15

Primary completion

2022-03-30

Completion

2022-03-30

Outcome

Missed primary endpoint

release “AVTX-007 data in multiple myeloma indicated the therapy is generally safe and well tolerated; no efficacy signal was seen at the high dose” avalotx.com ↗

Drugs

Indications